Condition (MeSH)
Xeroderma Pigmentosum
ClinicalTrials.gov lists 12 trials for Xeroderma Pigmentosum or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Xeroderma Pigmentosum itself; the rest are tagged with a narrower condition beneath it.
When did Xeroderma Pigmentosum trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2022 | 2 |
| 2021 | 2 |
| 2019 | 1 |
| 2018 | 2 |
| 2009 | 1 |
| 2004 | 1 |
| 2003 | 1 |
| 1999 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Xeroderma Pigmentosum trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Not applicable | 1 |
| Observational | 7 |
How many Xeroderma Pigmentosum trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Enrolling by invitation | 1 |
| Completed | 4 |
| Terminated | 1 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Xeroderma Pigmentosum trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| Clinuvel Europe Limited | 2 |
| Sol-Gel Technologies, Ltd. | 1 |
Which drugs are being tested for Xeroderma Pigmentosum? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Afamelanotide | 2 |
| NIVOLUMAB | 1 |
| IPILIMUMAB | 1 |
Interventions as named in the registry (2)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Patidegib Topical Gel, 2% | 1 |
| Patidegib Topical Gel, Vehicle | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Xeroderma Pigmentosum trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Myocardial Infarction | 1 | 1 |
| Respiratory syncytial virus infection | 1 | 1 |
Which publications cover Xeroderma Pigmentosum? (16)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Sunlight, Vitamin D, and Xeroderma Pigmentosum. | Advances in experimental medicine and biology | 2020 | Yes |
| Evaluation of a personalised adherence intervention to improve photoprotection in adults with Xeroderma Pigmentosum (XP): protocol for the trial of XPAND. | BMJ open | 2019 | Yes |
| Reproductive Health in Xeroderma Pigmentosum: Features of Premature Aging. | Obstetrics and gynecology | 2019 | Yes |
| An investigation of the predictors of photoprotection and UVR dose to the face in patients with XP: a protocol using observational mixed methods. | BMJ open | 2017 | Yes |
| Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. | Nature reviews. Genetics | 2009 | Yes |
Showing 5 of 16 publications.
Prevalence (27)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Xeroderma pigmentosum | Prevalence at birth | 1-9 / 1 000 000 | United Kingdom | GB | Unspecified |
| Xeroderma pigmentosum | Prevalence at birth | 1-9 / 1 000 000 | United Kingdom | GB | Exact |
| Xeroderma pigmentosum | Prevalence at birth | 1-9 / 1 000 000 | United Kingdom | GB | Exact |
| Xeroderma pigmentosum | Point prevalence | 1-9 / 1 000 000 | United States | US | Unspecified |
| Xeroderma pigmentosum | Point prevalence | 1-9 / 1 000 000 | United States | US | Exact |
Showing 5 of 27 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Xeroderma pigmentosum | 910 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Xeroderma pigmentosum | 910 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.